---
title: "Vaccinex FY25 Net Loss Narrows"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284727372.md"
description: "Vaccinex, Inc. reported a narrower net loss for FY25, decreasing to $5.26 million ($1.97 per share) from $18.63 million ($8.88 per share) the previous year. Collaboration and research revenue rose to $2.09 million from $0.60 million. Cash and cash equivalents at the end of the period were $0.140 million. The stock closed at $0.78, down 14.29%."
datetime: "2026-04-30T08:45:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284727372.md)
  - [en](https://longbridge.com/en/news/284727372.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284727372.md)
generator: "portal-rs"
---

# Vaccinex FY25 Net Loss Narrows

(RTTNews) - Vaccinex, Inc. (VCNX), a clinical-stage biotechnology firm, reported financial results for the full year 2025, reflecting a narrower net loss.

**Company Details**

Vaccinex engages in the discovery and development of targeted biotherapeutics for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. 

Its lead candidate, Pepinemab, is being developed for Alzheimer's and Huntington's disease and is also under evaluation in other oncology settings.

**2025 Results**

For the full year 2025, net loss attributable to Vaccinex shareholders shrank to $5.26 million, or $1.97 per share, from $18.63 million, or $8.88 per share, in the prior year.

Collaboration and research-based revenue increased to $2.09 million from $0.60 million in the prior year.

Cash and cash equivalents at the end of the period totalled $0.140 million.

VCNX has traded between $0.31 and $1.50 over the last year. The stock closed Wednesday's trade at $0.78, down 14.29%. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [VCNX.US](https://longbridge.com/en/quote/VCNX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [Alkem Laboratories Limited (NSE:ALKEM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/305559747.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Infomaniak plans Bulle data center to recover all server heat for district heating](https://longbridge.com/en/news/305572208.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**